Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 672
- Registration Number
- NCT02278120
- Locations
- 🇺🇸
Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Danbury Hospital SC, Danbury, Connecticut, United States
🇺🇸University Of California Los Angeles Dept of Onc, Los Angeles, California, United States
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 116
- Registration Number
- NCT02035813
- Locations
- 🇩🇪
University Hospital Ulm -Department of Gynecology, Ulm, Baden-Württemberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.